Name,Term,ES,NES,NOM p-val,FDR q-val,FWER p-val,Tag %,Gene %,Lead_genes
prerank,Ras signaling WP4223,0.7575149575662686,1.7699988209766382,0.0,0.015365084923831205,0.013,10/184,17.95%,SOS1;MAPK1;MAPK3;GAB1;AFDN;GAB2;RIN1;GRB2;PTPN11;RASA1
prerank,ErbB signaling pathway WP673,0.754980355355606,1.7689383379957453,0.0,0.007682542461915603,0.013,5/91,2.56%,SOS1;MAPK1;MAPK3;GAB1;CBLB
prerank,IL-2 signaling pathway WP49,0.8296588566268983,1.765248783256227,0.0,0.006697601120644371,0.015,6/42,14.96%,SOS1;MAPK1;MAPK3;GAB2;GRB2;PTPN11
prerank,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,0.7630382334754126,1.7586759041568838,0.0,0.005318683242864648,0.016,5/84,2.14%,SOS1;AXL;MAPK1;MAPK3;GAB1
prerank,T-cell receptor (TCR) signaling pathway WP69,0.7745351647191021,1.752474543791939,0.0,0.0047277184381019095,0.018,7/90,14.96%,SOS1;MAPK1;MAPK3;CBLB;GAB2;GRB2;PTPN11
prerank,Regulation of Actin Cytoskeleton WP51,0.722411396900812,1.7453540241558578,0.0,0.004530730169847663,0.021,7/150,14.10%,SOS1;MAPK1;MAPK3;ACTN1;ABI2;BCAR1;ACTB
prerank,EGF/EGFR signaling pathway WP437,0.6602919808277395,1.7238044719393888,0.0010718113612004287,0.008948895614978613,0.038,14/162,18.38%,SOS1;MAPK1;GAB1;CBLB;TNK2;INPPL1;GAB2;RIN1;GRB2;BCAR1;PTPN11;ERBB2;RASA1;CBLC
prerank,Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.7737903333485269,1.7120562850642136,0.0024183796856106408,0.010046401680966557,0.048,4/132,2.56%,SOS1;MAPK1;MAPK3;CBLB
prerank,Prolactin Signaling Pathway WP2037,0.7097553614742147,1.710100670991522,0.0023014959723820483,0.009061460339695326,0.049,8/76,15.38%,SOS1;MAPK1;MAPK3;SIRPA;GAB2;GRB2;PTPN11;ERBB2
prerank,Focal Adhesion WP306,0.6598999793789764,1.701717447675947,0.0010845986984815619,0.009219050954298721,0.054,9/198,15.38%,SOS1;MAPK1;MAPK3;TNK2;ACTN1;GRB2;BCAR1;ACTB;ERBB2
prerank,Leptin signaling pathway WP2034,0.7614382046684233,1.6855291865134494,0.0024691358024691358,0.01246398497317776,0.07,6/76,15.38%,SOS1;MAPK1;MAPK3;GRB2;PTPN11;ERBB2
prerank,Insulin Signaling WP481,0.7081441171407763,1.6818547656260427,0.005861664712778429,0.012410260900017511,0.073,10/160,21.79%,SOS1;MAPK1;MAPK3;GAB1;CBLB;INPPL1;GRB2;PTPN11;CBLC;PRKCD
prerank,MET in type 1 papillary renal cell carcinoma WP4205,0.7396289478924999,1.67525450641233,0.001183431952662722,0.012728472717966677,0.081,6/59,14.96%,SOS1;MAPK1;MAPK3;GAB1;GRB2;PTPN11
prerank,Nuclear Receptors Meta-Pathway WP2882,-0.6159463228336417,-1.6703045151829163,0.0639269406392694,0.19818063677712802,0.2688821752265861,3/319,8.97%,CDK1;IRS2;SRC
prerank,BDNF-TrkB Signaling WP3676,0.8718743733791097,1.6656715101972386,0.0,0.014014308227230658,0.091,5/34,12.82%,SOS1;MAPK1;GAB1;GAB2;GRB2
prerank,IL-4 signaling pathway WP395,0.7901396703803801,1.6519534970027283,0.0012594458438287153,0.015995447382244794,0.104,6/54,14.96%,SOS1;MAPK1;MAPK3;GAB2;GRB2;PTPN11
prerank,PDGF Pathway WP2526,0.8037186181304944,1.6435906989776712,0.006369426751592357,0.017728944142882157,0.116,7/40,17.95%,SOS1;MAPK1;MAPK3;GRB2;PTPN11;WASL;RASA1
prerank,IL-6 signaling pathway WP364,0.7841579033774799,1.6434757673628813,0.002531645569620253,0.01682511561795091,0.117,6/43,14.96%,SOS1;MAPK1;MAPK3;GAB1;GRB2;PTPN11
prerank,Alpha 6 Beta 4 signaling pathway WP244,0.7084179290299015,1.64236431724377,0.009445100354191263,0.01602171248467869,0.118,6/33,14.96%,SOS1;MAPK1;MAPK3;GAB1;GRB2;PTPN11
prerank,B Cell Receptor Signaling Pathway WP23,0.7081706169023767,1.6381061676384114,0.0035252643948296123,0.01654701453335668,0.127,7/97,14.96%,SOS1;MAPK1;GAB1;GAB2;DAPP1;GRB2;PTPN11
prerank,IL-5 signaling pathway WP127,0.7660996374936767,1.6199633656753325,0.006289308176100629,0.020447382244790757,0.15,5/40,14.96%,SOS1;MAPK1;MAPK3;GRB2;PTPN11
prerank,Melanoma WP4685,0.8179587527638755,1.6161328648022535,0.007989347536617843,0.020880756434950097,0.157,3/68,1.71%,SOS1;MAPK1;MAPK3
prerank,Signaling of Hepatocyte Growth Factor Receptor WP313,0.6910396671436758,1.6097703525751512,0.008158508158508158,0.022295490361503318,0.169,7/34,17.95%,SOS1;MAPK1;MAPK3;GAB1;GRB2;PTPN11;RASA1
prerank,ESC Pluripotency Pathways WP3931,0.7800399097986948,1.598760980499418,0.007741935483870968,0.025745510190098436,0.195,5/116,14.96%,SOS1;MAPK1;GAB1;GRB2;PTPN11
prerank,Hepatitis B infection WP4666,0.762889482709356,1.5986884924273164,0.011553273427471117,0.02477127473297146,0.195,3/152,1.71%,SOS1;MAPK1;MAPK3
prerank,Breast cancer pathway WP4262,0.7523922487444579,1.5875096440313285,0.013784461152882205,0.027704430047277184,0.214,5/154,15.38%,SOS1;MAPK1;MAPK3;GRB2;ERBB2
prerank,Gastrin signaling pathway WP4659,0.6459883177716179,1.5833423676980825,0.006779661016949152,0.02772988699271312,0.222,10/114,21.79%,SOS1;MAPK1;MAPK3;ANXA2;TJP1;GRB2;BCAR1;PTPN11;YES1;PRKCD
prerank,Regulation of toll-like receptor signaling pathway WP1449,0.8856438311566075,1.5820207642207202,0.0014641288433382138,0.027053055506916477,0.224,2/139,1.71%,MAPK1;MAPK3
prerank,RAC1/PAK1/p38/MMP2 Pathway WP3303,0.6973875709854443,1.580970294165984,0.004733727810650888,0.026340145583710634,0.227,7/68,17.95%,SOS1;MAPK1;MAPK3;GRB2;PTPN11;ERBB2;RASA1
prerank,Epithelial to mesenchymal transition in colorectal cancer WP4239,0.7341480106563947,1.5656859862040526,0.011111111111111112,0.03178983087689215,0.282,5/160,12.82%,SOS1;MAPK1;MAPK3;TJP1;GRB2
prerank,Non-small cell lung cancer WP4255,0.7685683139890855,1.56416668788165,0.0103359173126615,0.030234521946893658,0.285,5/72,15.38%,SOS1;MAPK1;MAPK3;GRB2;ERBB2
prerank,Endometrial cancer WP4155,0.7685683139890855,1.56416668788165,0.0103359173126615,0.030234521946893658,0.285,5/63,15.38%,SOS1;MAPK1;MAPK3;GRB2;ERBB2
prerank,MicroRNAs in cardiomyocyte hypertrophy WP1544,0.8632026128908719,1.5612051295431006,0.002824858757062147,0.02958405628691043,0.293,2/84,1.71%,MAPK1;MAPK3
prerank,Synaptic signaling pathways associated with autism spectrum disorder WP4539,0.8632026128908719,1.5612051295431006,0.002824858757062147,0.02958405628691043,0.293,2/50,1.71%,MAPK1;MAPK3
prerank,Kit receptor signaling pathway WP304,0.7030212292303557,1.5602896169478546,0.019559902200488997,0.02899203806894847,0.293,6/59,14.96%,SOS1;MAPK1;MAPK3;GAB2;GRB2;PTPN11
prerank,IL-3 signaling pathway WP286,0.7065945629446142,1.5580024701998774,0.0186799501867995,0.029041698976911726,0.297,6/49,14.96%,SOS1;MAPK1;MAPK3;GAB2;GRB2;PTPN11
prerank,Hepatitis C and Hepatocellular Carcinoma WP3646,0.8592100302387908,1.5480576182210084,0.004195804195804196,0.032470232883908254,0.32,4/49,14.96%,SOS1;MAPK3;GRB2;PTPN11
prerank,Fragile X Syndrome  WP4549,0.7106985592118903,1.5437446069272183,0.024390243902439025,0.033030140979711985,0.326,5/121,14.96%,SOS1;MAPK1;GAB1;GRB2;PTPN11
prerank,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement WP4560,0.7538815060587303,1.5391132010141917,0.020860495436766623,0.03433816549779281,0.342,4/18,11.54%,MAPK1;MAPK3;ACTN1;TJP1
prerank,MAPK Signaling Pathway WP382,0.7360137887050316,1.5328127767027087,0.01982651796778191,0.03609431192166265,0.363,6/246,21.79%,SOS1;MAPK1;MAPK3;GRB2;RASA1;PRKCD
prerank,Envelope proteins and their potential roles in EDMD physiopathology WP4535,0.8380864132100305,1.5243782963641066,0.013831258644536652,0.039062773594817024,0.387,3/46,1.71%,SOS1;MAPK1;MAPK3
prerank,Ebola Virus Pathway on Host WP4217,0.7334748508137097,1.5207064829047146,0.021464646464646464,0.03975319345208861,0.398,5/129,14.10%,AXL;MAPK1;MAPK3;ACTN1;ACTB
prerank,RANKL/RANK signaling pathway WP2018,0.7041118775749415,1.5186778606755695,0.02696078431372549,0.04004490081797033,0.402,3/55,8.55%,MAPK1;MAPK3;GAB2
prerank,Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864,0.8300495859746557,1.5167305396263866,0.009790209790209791,0.03993822610791903,0.407,1/53,1.28%,MAPK1
prerank,Chemokine signaling pathway WP3929,0.641598718143008,1.507362787617734,0.020954598370197905,0.04373139555244266,0.44,6/164,16.67%,SOS1;MAPK1;MAPK3;GRB2;BCAR1;WASL
prerank,Small cell lung cancer WP4658,-0.6870084902562839,-1.5043765083511182,0.06752411575562701,0.22011046133853152,0.45317220543806647,3/96,17.09%,CDK2;ITGB1;PIK3R3
prerank,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.7272802464171488,1.4982557864625947,0.02802547770700637,0.047224654176151286,0.457,4/66,15.38%,SOS1;MAPK1;GRB2;ERBB2
prerank,Acute viral myocarditis WP4298,0.7439241804813701,1.4928136949061757,0.03015075376884422,0.049101467039199716,0.47,5/86,17.95%,SOS1;MAPK1;MAPK3;ACTB;RASA1
prerank,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.644048909506498,1.4889246232307527,0.03356481481481482,0.05049605650908846,0.481,3/303,1.71%,SOS1;MAPK1;MAPK3
prerank,EPO Receptor Signaling WP581,0.7234815758679061,1.4709489494207297,0.04247104247104247,0.060204539485203996,0.538,5/26,17.95%,SOS1;MAPK1;MAPK3;GRB2;RASA1
prerank,Netrin-UNC5B signaling pathway WP4747,0.7346505189415409,1.4640921828530176,0.031578947368421054,0.06343826271534704,0.56,3/52,14.96%,MAPK1;MAPK3;PTPN11
prerank,PDGFR-beta pathway WP3972,0.8034740057215358,1.4577311180973995,0.04120879120879121,0.06673174575380844,0.577,4/29,17.95%,SOS1;MAPK3;GRB2;RASA1
prerank,Regulatory circuits of the STAT3 signaling pathway WP4538,0.766641145342804,1.4530635797191744,0.05737704918032787,0.06841286681018055,0.594,2/78,1.71%,MAPK1;MAPK3
prerank,Thyroid hormones production and their peripheral downstream signaling effects WP4746,0.7857093669208521,1.4529343178620184,0.04261363636363636,0.06716542300284202,0.594,3/95,12.82%,SOS1;MAPK1;GRB2
prerank,DNA damage response (only ATM dependent) WP710,0.7207293889110626,1.4521105159826388,0.040214477211796246,0.06643336427879994,0.596,4/110,15.38%,SOS1;MAPK1;GRB2;ERBB2
prerank,Translation inhibitors in chronically activated PDGFRA cells WP4566,0.7683601092780827,1.444436925574076,0.04456824512534819,0.0706969007179128,0.619,2/46,1.71%,MAPK1;MAPK3
prerank,Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.6173395844306425,1.44397948515646,0.049338146811071,0.06964788844494675,0.62,6/144,15.81%,MAPK1;MAPK3;SIRPA;GRB2;PTPN11;EIF2S2
prerank,PI3K-Akt signaling pathway WP4172,0.6058174132325786,1.4422799680329763,0.05034324942791762,0.06956499987492808,0.625,3/340,1.71%,SOS1;MAPK1;MAPK3
prerank,Osteoblast differentiation WP4787,0.7925833569995764,1.4257970822749284,0.0460431654676259,0.07966620280345409,0.671,2/118,1.71%,MAPK1;MAPK3
prerank,Interleukin-11 Signaling Pathway WP2332,0.6862563118689042,1.3925761535238388,0.07682119205298013,0.10307241318930799,0.742,5/44,21.37%,MAPK1;MAPK3;GRB2;PTPN11;YES1
prerank,Oncostatin M Signaling Pathway WP2374,0.6063067940381679,1.3891142607742037,0.08971291866028708,0.1039697402277496,0.748,5/65,14.96%,SOS1;MAPK1;MAPK3;GRB2;PTPN11
prerank,AGE/RAGE pathway WP2324,0.698801418932268,1.3771708411539902,0.09115281501340483,0.11179084223428472,0.78,2/66,1.71%,MAPK1;MAPK3
prerank,Glioblastoma signaling pathways WP2261,0.6151200287693611,1.3641995137905867,0.10877626699629171,0.12129310419064733,0.817,5/82,15.38%,MAPK1;MAPK3;GAB1;GRB2;ERBB2
prerank,Thyroid stimulating hormone (TSH) signaling pathway WP2032,0.6906596235827303,1.3502438371929506,0.11869031377899045,0.1318614049852859,0.842,2/66,1.71%,MAPK1;MAPK3
prerank,Integrin-mediated Cell Adhesion WP185,0.5705668591807398,1.3471481096513669,0.0996523754345307,0.13265752807864523,0.848,4/101,13.68%,SOS1;MAPK1;GRB2;BCAR1
prerank,Nanoparticle-mediated activation of receptor signaling WP2643,0.6452393415240786,1.3430316381307836,0.10913705583756345,0.13429675188233234,0.856,3/28,12.82%,SOS1;MAPK1;GRB2
prerank,IL-18 signaling pathway WP4754,0.741668628720874,1.3346212545054275,0.11235955056179775,0.13974044691081985,0.871,2/272,1.71%,MAPK1;MAPK3
prerank,Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway WP2203,0.623081529741084,1.326549340861046,0.12421580928481807,0.1452698938253132,0.88,6/47,26.50%,MAPK1;MAPK3;GAB2;PTPN11;YES1;LYN
prerank,Pancreatic adenocarcinoma pathway WP4263,0.6346575792445297,1.2873515246798286,0.15334207077326342,0.1843280968646524,0.926,4/89,21.79%,MAPK1;MAPK3;ERBB2;PRKCD
prerank,VEGFA-VEGFR2 Signaling Pathway WP3888,0.43545206402635334,1.167941189035272,0.2542194092827004,0.33431226631783867,0.99,11/432,22.22%,MAPK1;MAPK3;GAB1;AFDN;CTNND1;GRB2;BCAR1;PTPN11;ANXA1;PRKCD;DOK1
prerank,Head and Neck Squamous Cell Carcinoma WP4674,0.6283947960956593,1.1622403831054648,0.2552011095700416,0.3372781740805311,0.991,2/73,15.38%,GAB1;ERBB2
prerank,G13 Signaling Pathway WP524,0.6234462963435852,1.1452607488510778,0.319060773480663,0.35626735372839385,0.993,2/39,16.67%,TNK2;WASL
prerank,7q11.23 copy number variation syndrome WP4932,0.6146376498230811,1.1083236393872782,0.34217877094972066,0.40398686991498983,0.996,2/104,12.82%,MAPK3;GRB2
prerank,Bladder cancer WP2828,0.5829220991965224,1.0689760582217425,0.4253521126760563,0.45574877429521976,0.998,2/40,15.38%,MAPK1;ERBB2
prerank,TGF-beta Signaling Pathway WP366,0.4389956088685891,1.0279968314554058,0.46436781609195404,0.511532658675999,0.999,4/132,13.68%,SOS1;MAPK1;GRB2;BCAR1
prerank,Notch Signaling Pathway Netpath WP61,-0.46101475318283325,-1.014351327281846,0.4136690647482014,0.8228286766298463,0.9073514602215509,3/61,20.09%,SRC;ITCH;JAK2
prerank,Spinal Cord Injury WP2431,0.4913974030666772,0.9418869614795078,0.6063829787234043,0.6326358095093869,1.0,2/118,1.71%,MAPK1;MAPK3
prerank,Pathways Regulating Hippo Signaling WP4540,0.5161742076381544,0.9313065710589159,0.6027777777777777,0.6394711959376641,1.0,3/98,33.33%,PRKCD;EGFR;EPHA2
prerank,Pathways in clear cell renal cell carcinoma WP4018,0.4735381982384743,0.9186761679072406,0.6162943495400789,0.6487082868702135,1.0,5/85,39.74%,PFKP;ACLY;EGFR;PKM;PGM1
prerank,Integrated breast cancer pathway WP1984,0.4544200974003611,0.8985305563876629,0.6404199475065617,0.6676367320300082,1.0,1/152,1.28%,MAPK1
prerank,Arrhythmogenic Right Ventricular Cardiomyopathy WP2118,0.44808602091445815,0.8410852018237329,0.7131474103585658,0.7313719811968806,1.0,3/74,28.21%,ACTN1;ACTB;DSP
prerank,Interferon type I signaling pathways WP585,0.40703760888081114,0.8364446747730837,0.7020460358056266,0.7281883285420763,1.0,2/54,14.96%,GAB2;PTPN11
prerank,Pathogenic Escherichia coli infection WP2272,0.3887126963556175,0.8050331005026246,0.7626076260762608,0.7560508229732097,1.0,3/55,20.09%,ACTB;WASL;ARPC3
prerank,Hippo-Merlin Signaling Dysregulation WP4541,-0.3157894736842111,-0.7512805832196252,0.7818930041152263,1.0,0.9899295065458208,6/120,69.66%,ITGB1;MET;PTK2;ITGB4;EPHA2;EGFR
prerank,Primary focal segmental glomerulosclerosis (FSGS) WP2572,-0.274336283185841,-0.7363053103666092,0.8153153153153153,0.9690058479532163,0.9899295065458208,8/72,73.93%,ITGB1;TLN1;PTK2;ITGB4;VCL;KRT8;MYH9;CD2AP
prerank,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms WP4534,0.3902080757531352,0.7028181704356375,0.8783592644978784,0.8520399229556995,1.0,2/47,20.51%,ACTB;LIMD1
prerank,Androgen receptor signaling pathway WP138,-0.3144104803493453,-0.6869969092430717,0.8817567567567568,0.8723738358241282,0.9909365558912386,5/90,69.66%,SRC;PTK2;FHL2;PIK3R2;EGFR
